Newsbenzinga
Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study
· Published
Article summary
Rezolute says 6 of 8 patients met the primary endpoint in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism.
An excerpt from the original article.
Comments —
Loading comments…